Relations among serum ferritin, C282Y and H63D mutations in the HFE gene and type 2 diabetes mellitus in the Czech population

K. Kaňková; E. H. J. M. Jansen; I. Márová; A. Stejskalová; L. Pácal; J. Mužík; J. Vácha

doi:10.1055/s-2002-33071

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2002; 110(5): 223-229
DOI: 10.1055/s-2002-33071

Articles

Relations among serum ferritin, C282Y and H63D mutations in the HFE gene and type 2 diabetes mellitus in the Czech population

K. Kaňková¹ , E. H. J. M Jansen² , I. Márová³ , A. Stejskalová¹ , L. Pácal¹ , J. Mužík¹ , J. Vácha¹

¹ Department of Pathophysiology, Faculty of Medicine, Masaryk University Brno, Czech Republic
² Laboratory for Health Effects Research, National Institute of Public Health and Environment, Bilthoven, The Netherlands
³ Department of Food Chemistry and Biotechnology, Faculty of Chemistry, Technical University, Brno, Czech Republic

Abstract

Summary

Aims of the study were: (i) to determine the prevalence of mutations C282Y and H63D in the HFE gene causing hereditary hemochromatosis in patients with type 2 diabetes mellitus and non-diabetics, (ii) to investigate the relationship among HFE genotypes, serum ferritin and glucose intolerance and (iii) to assess possible association of HFE mutations with the susceptibility to develop late diabetic complications in the Czech population. Two approaches were employed - the case-control study comprising diabetics and non-diabetic controls (n = 326) and the cross-sectional study comprising subjects with a previously unknown defect of glucose tolerance (n = 113, oral glucose tolerance test performed in each subject). Allele frequencies of C282Y and H63D did not differ between diabetic and control groups nor among subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and diabetes. Ferritin levels significantly differed between diabetic and non-diabetic women (P<1.10^-3) and among subjects with NGT, IGT and diabetes (P<0.05). Differences in ferritin levels related to particular genotypes of C282Y and H63D were not detected. Prevalence of diabetes in the first and second quartiles of ferritin distribution differed highly significantly from the prevalence in the third and fourth quartiles in women (P = 0.000037), OR = 3.50 (95% CI, 1.89-6.48). The extent of diabetic late complications did not correlate with ferritin plasma levels.

Key words:

Type 2 diabetes mellitus - Ferritin - Hereditary hemochromatosis - HFE - Diabetic complications - Iron

Full Text

References

1 Baynes J W. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991; 4 405-412
2 Baynes J W, Thorpe S R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999; 1 1-9
3 Byrnes V, Ryan E, Barrett S, Kenny P, Mayne P, Crowe J. Genetic hemochromatosis, a Celtic disease: is it now time for population screening?. Genet Test. 2001; 5 127-130
4 Carella M, D'Ambrosio L, Totaro A, Grifa A, Valentino M A, Piperno A, Girelli D, Roetto A, Franco B, Gasparini P, Camaschella C. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet. 1997; 4 828-832
5 Conte D, Manachino D, Colli A, Guala A, Aimo G, Andreoletti M, Cornetti M, Fraquelli M. Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med. 1998; 5 370-373
6 David V, Jouanolle A M, Fergelot P, Brissot P, Deugnier Y, Le Gall J Y. Molecular genetics of hemochromatosis. Ann Endocrinol (Paris). 1999; 3 204-209
7 Dubois-Laforgue D, Caillat-Zucman S, Djilali-Saiah I, Larger E, Mercadier A, Boitard C, Bach J F, Timsit J. Mutations in HFE, the hemochromatosis candidate gene, in patients with NIDDM. Diabetes Care. 1998; 8 1371-1372
8 Dubois-Laforgue D, Caillat-Zucman S, Boitard C, Timsit J. Clinical characteristics of type 2 diabetes in patients with mutations of HFE. Diabetes Metab. 2000; 1 65-68
9 Ellervik C, Mandrup-Poulsen T, Nordestgaard B G, Larsen L E, Appleyard M, Frandsen M, Petersen P, Schlichting P, Saermark T, Tybjaerg-Hansen A, Birgens H. Prevalence of hereditary aemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet. 2001; 358 1405-1409
10 Eshed I, Elis A, Lishner M. Plasma ferritin and type 2 diabetes mellitus: a critical review. Endocr Res. 2001; 27 91-97
11 Feder J N, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy D A, Basava A, Dormishian F, Domingo R, Ellis M C, Fullan A, Hinton L M, Jones N L, Kimmel B E, Kronmal G S, Lauer P, Lee V K, Loeb D B, Mapa F A, McClelland E, Meyer N C, Mintier G A, Moeller N, Moore T, Morikang E, Prass C E, Quintana L, Starnes S M, Schatzman R C, Brunke K J, Drayna D T, Rischl N J, Bacon B R, Wolff R K. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996; 4 399-408
12 Feder J N, Penny D M, Irrinki A, Lee V K, Lebron J A, Watson N, Tsuchihashi Z, Sigal E, Bjorkman P J, Schatzman R C. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA. 1998; 4 1472-1477
13 Fernandez-Real J M, Ricart-Engel W, Arroyo E, Balanca R, Casamitjana-Abella R, Cabrero D, Fernandez-Castaner M, Soler J. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care. 1998; 1 62-68
14 Fernandez-Real J M, Vendrell J, Baiget M, Gimferrer E, Ricart W. C282Y and H63D mutations of the hemochromatosis candidate gene in type 2 diabetes. Diabetes Care. 1999; 3 525-526
15 Ford E S, Cogswell M E. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care. 1999; 12 1978-1983
16 Frayling T, Ellard S, Grove J, Walker M, Hattersley A T. C282Y mutation in HFE (haemochromatosis) gene and type 2 diabetes. Lancet. 1998; 9120 1933-1934
17 Gochee P A, Powell L W. What's new in hemochromatosis. Curr Opin Hematol. 2001; 2 98-104
18 Griffiths W J, Kelly A L, Smith S J, Cox T M. Localization of iron transport and regulatory proteins in human cells. QJM. 2000; 9 575-587
19 Griffiths W J, Sly W S, Cox T M. Intestinal iron uptake determined by divalent metal transporter is enhanced in HFE-deficient mice with hemochromatosis. Gastroenterology. 2001; 6 1420-1429
20 Hramiak I M, Finegood D T, Adams P C. Factors affecting glucose tolerance in hereditary hemochromatosis. Clin Invest Med. 1997; 2 110-118
21 Jeffrey G P, Chakrabarti S, Hegele R A, Adams P C. Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. Nat. Genet.. 1999; 4 325-326
22 Kaňková K, Márová I, Záhejský J, Mužík A, Znojil V, Vácha J. Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism. 2001; 10 1152-1160
23 Mowri H O, Frei B, Keaney J F. Glucose enhancement of LDL oxidation is strictly metal ion dependent. Free Radic Biol Med. 2000; 9 814-824
24 Nedstrand E, Pertl J, Hammar M. Climacteric symptoms in a postmenopausal Czech population. Maturitas. 1996; 23 85-89
25 Orino K, Lehman L, Tsuji Y, Ayaki H, Torti F M. Ferritin and the response to oxidative stress. Biochem J. 2001; 1 241-247
26 Parkkila S, Waheed A, Britton R S, Feder J N, Tsuchihashi Z, Schatzman R C, Bacon B R, Sly W S. Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc Natl Acad Sci USA. 1997; 6 2534-2539
27 Phelps G, Chapman I, Hall P, Braund W, Mackinnon M. Prevalence of genetic haemochromatosis among diabetic patients. Lancet. 1989; 8657 33-234
28 Qian M, Liu M, Eaton J W. Transition metals bind to glycated proteins forming redox active “glycochelates”: implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun. 1998; 2 385-389
29 Qian M, Eaton J W. Glycochelates and the etiology of diabetic peripheral neuropathy. Free Radic Biol Med. 2000; 4 652-656
30 Rahier J, Loozen S, Goebbels R M, Abrahem M. The haemochromatotic human pancreas: a quantitative immunohistochemical and ultrastructural study. Diabetologia. 1987; 1 5-12
31 Rochette J, Pointon J J, Fisher C A, Perera G, Arambepola M, Arichchi D S, De Silva S, Vandwalle J L, Monti J P, Old J M, Merryweather-Clarke A T, Weatherall D J, Robson K J. Multicentric origin of hemochromatosis gene (HFE) mutations. Am J Hum Genet. 1999; 4 1056-1062
32 Ryab E, O'keane C, Crowe J. Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis. 1998; 24 428-432
33 Salonen J T, Tuomainen T P, Nyyssonen K, Lakka H M, Punnonen K. Relation between iron stores and non-insulin dependent diabetes in men: case-control study. BMJ. 1998; 7160 727
34 Sampson M J, Williams T, Heyburn P J, Greenwood R H, Temple R C, Wimperis J Z, Jennings B A, Willis G A. Prevalence of HFE (hemochromatosis gene) mutations in unselected male patients with type 2 diabetes. J Lab Clin Med. 2000; 2 170-173
35 Thorbe S R, Baynes J W. Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging. 1996; 2 69-77
36 Tuomainen T P, Nyyssonen K, Salonen R, Tervahauta A, Korpela H, Lakka T, Kaplan G A, Salonen J T. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 eastern Finnish men Diabetes Carey 1997 3: 426-428
37 Turnbull A J, Mitchison H C, Peaston R T, Lai L C, Bennett M K, Taylor R, Bassendine M F. The prevalence of hereditary haemochromatosis in a diabetic population. QJM. 1997; 4 271-275
38 Waheed A, Parkkila S, Zhou X Y, Tomatsu S, Tsuchihashi Z, Feder J N, Schatzman R C, Britton R S, Bacon B R, Sly W S. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA. 1997; 23 12384-12389

Kateřina KaňkováMD, PhD

Masaryk University

Faculty of Medicine

Department of Pathophysiology

Komenského nám. 2

66243 Brno

Czech Republic

Phone: +420-5-42126556

Fax: +420-5-42126550

Email: kankov@med.muni.cz